Investment
Features
FeesSafety
Academy
More
Pluang+

Anthropic commits 5% shares to public fund; Elon Musk pledges SpaceX shares to American kids.

Market News
19 Oct 2026
Fox Business
View Source
Bullish
Anthropic commits 5% shares to public fund; Elon Musk pledges SpaceX shares to American kids.

Anthropic announced it will allocate 5% of its shares to a new Public Benefit Fund aimed at supporting nonprofits or direct donations, potentially increasing to 20% based on company growth. The company has not clarified if shares will be distributed directly to Americans. Elon Musk urged Anthropic to give shares directly to the public and pledged to give one SpaceX share to every child in America next year. This move has drawn public attention and support from figures like former President Donald Trump, highlighting a unique approach to wealth distribution and public benefit in the tech sector.

Anthropic's share distribution plans and Elon Musk's SpaceX pledge provide context for the current market environment. For readers following Technology-sector US stocks on Pluang, here is the market snapshot as of Oct 20, 2026 05:21 WIB: out of 150 priced stocks, 109 rose and 37 fell. Notable movers include AXTI at USD 57.32 with a 1-day change of +11.37% and a typical hold time of 17 days, DOCN at USD 97.94 down 10.53% with a 43-day hold time and 100% buy order activity, and APLD at USD 19.32 up 7.04% with a 25-day hold time and 53% buy order activity.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App